Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Viral Targeting of Non-Muscle-Invasive Bladder Cancer and Priming of Antitumor Immunity Following Intravesical Coxsackievirus A21.

Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, Sandhu SS, Melcher AA, Harrington KJ, Davies B, Au G, Grose M, Bagwan I, Fox B, Vile R, Mostafid H, Shafren D, Pandha HS.

Clin Cancer Res. 2019 Jul 4. doi: 10.1158/1078-0432.CCR-18-4022. [Epub ahead of print]

PMID:
31273010
2.

Kinase Regulation of HOX Transcription Factors.

Primon M, Hunter KD, Pandha HS, Morgan R.

Cancers (Basel). 2019 Apr 10;11(4). pii: E508. doi: 10.3390/cancers11040508. Review.

3.

Membrane insertion and secretion of the Engrailed-2 (EN2) transcription factor by prostate cancer cells may induce antiviral activity in the stroma.

Punia N, Primon M, Simpson GR, Pandha HS, Morgan R.

Sci Rep. 2019 Mar 26;9(1):5138. doi: 10.1038/s41598-019-41678-0.

4.

Adjuvant sunitinib in patients with high-risk renal cell carcinoma: safety, therapy management, and patient-reported outcomes in the S-TRAC trial.

Staehler M, Motzer RJ, George DJ, Pandha HS, Donskov F, Escudier B, Pantuck AJ, Patel A, DeAnnuntis L, Bhattacharyya H, Ramaswamy K, Zanotti G, Lin X, Lechuga M, Serfass L, Paty J, Ravaud A.

Ann Oncol. 2018 Oct 1;29(10):2098-2104. doi: 10.1093/annonc/mdy329.

5.

Phase III Trial of Adjuvant Sunitinib in Patients with High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Donskov F, Escudier B, Li S, Casey M, Valota O, Laguerre B, Pantuck AJ, Pandha HS, Patel A, Lechuga M, Ravaud A.

Clin Cancer Res. 2019 Feb 15;25(4):1165-1173. doi: 10.1158/1078-0432.CCR-18-1724. Epub 2018 Nov 6.

6.

Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.

George DJ, Martini JF, Staehler M, Motzer RJ, Magheli A, Escudier B, Gerletti P, Li S, Casey M, Laguerre B, Pandha HS, Pantuck AJ, Patel A, Lechuga MJ, Ravaud A.

Clin Cancer Res. 2018 Apr 1;24(7):1554-1561. doi: 10.1158/1078-0432.CCR-17-2822. Epub 2018 Jan 26.

7.

Genetically modified lentiviruses that preserve microvascular function protect against late radiation damage in normal tissues.

Khan AA, Paget JT, McLaughlin M, Kyula JN, Wilkinson MJ, Pencavel T, Mansfield D, Roulstone V, Seth R, Halle M, Somaiah N, Boult JKR, Robinson SP, Pandha HS, Vile RG, Melcher AA, Harris PA, Harrington KJ.

Sci Transl Med. 2018 Jan 24;10(425). pii: eaar2041. doi: 10.1126/scitranslmed.aar2041.

8.

Inhibition of HOX/PBX dimer formation leads to necroptosis in acute myeloid leukemia cells.

Alharbi RA, Pandha HS, Simpson GR, Pettengell R, Poterlowicz K, Thompson A, Harrington K, El-Tanani M, Morgan R.

Oncotarget. 2017 Aug 7;8(52):89566-89579. doi: 10.18632/oncotarget.20023. eCollection 2017 Oct 27.

9.

Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.

Motzer RJ, Ravaud A, Patard JJ, Pandha HS, George DJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Casey M, Serfass L, Pantuck AJ, Staehler M.

Eur Urol. 2018 Jan;73(1):62-68. doi: 10.1016/j.eururo.2017.09.008. Epub 2017 Sep 28.

10.

Targeting HOX/PBX dimers in cancer.

Morgan R, El-Tanani M, Hunter KD, Harrington KJ, Pandha HS.

Oncotarget. 2017 May 9;8(19):32322-32331. doi: 10.18632/oncotarget.15971. Review.

11.

Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma.

Iyer R, Montgomery B, Pandha HS.

Indian J Urol. 2017 Jan-Mar;33(1):76-78. doi: 10.4103/0970-1591.194787.

12.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators.

N Engl J Med. 2016 Dec 8;375(23):2246-2254. Epub 2016 Oct 9.

13.

Science in Focus - Oncolytic Viruses: New Multifunctional Immunotherapeutics.

Pandha HS.

Clin Oncol (R Coll Radiol). 2016 Oct;28(10):615-8. doi: 10.1016/j.clon.2016.06.014. Epub 2016 Jul 25. No abstract available.

PMID:
27461856
14.

HOX transcription factors are potential targets and markers in malignant mesothelioma.

Morgan R, Simpson G, Gray S, Gillett C, Tabi Z, Spicer J, Harrington KJ, Pandha HS.

BMC Cancer. 2016 Feb 11;16:85. doi: 10.1186/s12885-016-2106-7.

15.

Oncolytic vaccinia virus as a vector for therapeutic sodium iodide symporter gene therapy in prostate cancer.

Mansfield DC, Kyula JN, Rosenfelder N, Chao-Chu J, Kramer-Marek G, Khan AA, Roulstone V, McLaughlin M, Melcher AA, Vile RG, Pandha HS, Khoo V, Harrington KJ.

Gene Ther. 2016 Apr;23(4):357-68. doi: 10.1038/gt.2016.5. Epub 2016 Jan 27.

16.

Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors.

Roulstone V, Khan K, Pandha HS, Rudman S, Coffey M, Gill GM, Melcher AA, Vile R, Harrington KJ, de Bono J, Spicer J.

Clin Cancer Res. 2015 Mar 15;21(6):1305-12. doi: 10.1158/1078-0432.CCR-14-1770. Epub 2014 Nov 25.

17.

Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.

de Bono JS, Piulats JM, Pandha HS, Petrylak DP, Saad F, Aparicio LM, Sandhu SK, Fong P, Gillessen S, Hudes GR, Wang T, Scranton J, Pollak MN.

Clin Cancer Res. 2014 Apr 1;20(7):1925-34. doi: 10.1158/1078-0432.CCR-13-1869. Epub 2014 Feb 17.

18.

Targeting HOX transcription factors in prostate cancer.

Morgan R, Boxall A, Harrington KJ, Simpson GR, Michael A, Pandha HS.

BMC Urol. 2014 Feb 5;14:17. doi: 10.1186/1471-2490-14-17.

19.

Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.

Kyula JN, Khan AA, Mansfield D, Karapanagiotou EM, McLaughlin M, Roulstone V, Zaidi S, Pencavel T, Touchefeu Y, Seth R, Chen NG, Yu YA, Zhang Q, Melcher AA, Vile RG, Pandha HS, Ajaz M, Szalay AA, Harrington KJ.

Oncogene. 2014 Mar 27;33(13):1700-12. doi: 10.1038/onc.2013.112. Epub 2013 Apr 29.

20.

The abrogation of the HOXB7/PBX2 complex induces apoptosis in melanoma through the miR-221&222-c-FOS pathway.

Errico MC, Felicetti F, Bottero L, Mattia G, Boe A, Felli N, Petrini M, Bellenghi M, Pandha HS, Calvaruso M, Tripodo C, Colombo MP, Morgan R, Carè A.

Int J Cancer. 2013 Aug 15;133(4):879-92. doi: 10.1002/ijc.28097. Epub 2013 Mar 13.

21.

Senescence evasion in melanoma progression: uncoupling of DNA-damage signaling from p53 activation and p21 expression.

Mackenzie Ross AD, Cook MG, Chong H, Hossain M, Pandha HS, Bennett DC.

Pigment Cell Melanoma Res. 2013 Mar;26(2):226-35. doi: 10.1111/pcmr.12060. Epub 2013 Jan 14.

22.

The role of HOX genes in normal hematopoiesis and acute leukemia.

Alharbi RA, Pettengell R, Pandha HS, Morgan R.

Leukemia. 2013 Apr;27(5):1000-8. doi: 10.1038/leu.2012.356. Epub 2012 Dec 5. Review.

PMID:
23212154
23.

Targeting the HOX/PBX dimer in breast cancer.

Morgan R, Boxall A, Harrington KJ, Simpson GR, Gillett C, Michael A, Pandha HS.

Breast Cancer Res Treat. 2012 Nov;136(2):389-98. doi: 10.1007/s10549-012-2259-2. Epub 2012 Sep 30.

PMID:
23053648
24.

Oncolytic Vaccinia virus and radiotherapy in head and neck cancer.

Mansfield D, Pencavel T, Kyula JN, Zaidi S, Roulstone V, Thway K, Karapanagiotou L, Khan AA, McLaughlin M, Touchefeu Y, Seth R, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

Oral Oncol. 2013 Feb;49(2):108-18. doi: 10.1016/j.oraloncology.2012.07.019. Epub 2012 Aug 25.

PMID:
22925693
25.

Reovirus exerts potent oncolytic effects in head and neck cancer cell lines that are independent of signalling in the EGFR pathway.

Twigger K, Roulstone V, Kyula J, Karapanagiotou EM, Syrigos KN, Morgan R, White C, Bhide S, Nuovo G, Coffey M, Thompson B, Jebar A, Errington F, Melcher AA, Vile RG, Pandha HS, Harrington KJ.

BMC Cancer. 2012 Aug 24;12:368. doi: 10.1186/1471-2407-12-368.

26.

Synergistic cytotoxicity of oncolytic reovirus in combination with cisplatin-paclitaxel doublet chemotherapy.

Roulstone V, Twigger K, Zaidi S, Pencavel T, Kyula JN, White C, McLaughlin M, Seth R, Karapanagiotou EM, Mansfield D, Coffey M, Nuovo G, Vile RG, Pandha HS, Melcher AA, Harrington KJ.

Gene Ther. 2013 May;20(5):521-8. doi: 10.1038/gt.2012.68. Epub 2012 Aug 16.

27.

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies.

Karapanagiotou EM, Roulstone V, Twigger K, Ball M, Tanay M, Nutting C, Newbold K, Gore ME, Larkin J, Syrigos KN, Coffey M, Thompson B, Mettinger K, Vile RG, Pandha HS, Hall GD, Melcher AA, Chester J, Harrington KJ.

Clin Cancer Res. 2012 Apr 1;18(7):2080-9. doi: 10.1158/1078-0432.CCR-11-2181. Epub 2012 Feb 7.

28.

Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for superficial bladder cancer.

Simpson GR, Horvath A, Annels NE, Pencavel T, Metcalf S, Seth R, Peschard P, Price T, Coffin RS, Mostafid H, Melcher AA, Harrington KJ, Pandha HS.

Br J Cancer. 2012 Jan 31;106(3):496-507. doi: 10.1038/bjc.2011.577. Epub 2012 Jan 12.

29.

Are we ready to start studies of Th17 cell manipulation as a therapy for cancer?

Middleton GW, Annels NE, Pandha HS.

Cancer Immunol Immunother. 2012 Jan;61(1):1-7. doi: 10.1007/s00262-011-1151-y. Epub 2011 Nov 16. Review.

PMID:
22086162
30.

Antiangiogenic effects of zoledronate on cancer neovasculature.

Metcalf S, Pandha HS, Morgan R.

Future Oncol. 2011 Nov;7(11):1325-33. doi: 10.2217/fon.11.113. Review.

PMID:
22044205
31.

HOX genes in ovarian cancer.

Kelly ZL, Michael A, Butler-Manuel S, Pandha HS, Morgan RG.

J Ovarian Res. 2011 Sep 9;4:16. doi: 10.1186/1757-2215-4-16.

32.

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer.

Heinemann L, Simpson GR, Boxall A, Kottke T, Relph KL, Vile R, Melcher A, Prestwich R, Harrington KJ, Morgan R, Pandha HS.

BMC Cancer. 2011 Jun 6;11:221. doi: 10.1186/1471-2407-11-221.

33.

The roles of cell surface attachment molecules and coagulation Factor X in adenovirus 5-mediated gene transfer in pancreatic cancer cells.

Hamdan S, Verbeke CS, Fox N, Booth J, Bottley G, Pandha HS, Blair GE.

Cancer Gene Ther. 2011 Jul;18(7):478-88. doi: 10.1038/cgt.2011.17. Epub 2011 May 13.

PMID:
21566668
34.

HOX genes in pancreatic development and cancer.

Gray S, Pandha HS, Michael A, Middleton G, Morgan R.

JOP. 2011 May 6;12(3):216-9.

35.

Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.

Ilett EJ, Bárcena M, Errington-Mais F, Griffin S, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Limpens RW, Mommaas M, Hoeben RC, Vile RG, Melcher AA.

Clin Cancer Res. 2011 May 1;17(9):2767-76. doi: 10.1158/1078-0432.CCR-10-3266. Epub 2011 Mar 9.

36.

REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer.

Comins C, Spicer J, Protheroe A, Roulstone V, Twigger K, White CM, Vile R, Melcher A, Coffey MC, Mettinger KL, Nuovo G, Cohn DE, Phelps M, Harrington KJ, Pandha HS.

Clin Cancer Res. 2010 Nov 15;16(22):5564-72. doi: 10.1158/1078-0432.CCR-10-1233. Epub 2010 Oct 6.

37.

The effect of cell cycle synchronization on tumor sensitivity to reovirus oncolysis.

Heinemann L, Simpson GR, Annels NE, Vile R, Melcher A, Prestwich R, Harrington KJ, Pandha HS.

Mol Ther. 2010 Dec;18(12):2085-93. doi: 10.1038/mt.2010.189. Epub 2010 Sep 14.

38.

Expression of RNA interference triggers from an oncolytic herpes simplex virus results in specific silencing in tumour cells in vitro and tumours in vivo.

Anesti AM, Simpson GR, Price T, Pandha HS, Coffin RS.

BMC Cancer. 2010 Sep 13;10:486. doi: 10.1186/1471-2407-10-486.

39.

Therapeutic effect of sodium iodide symporter gene therapy combined with external beam radiotherapy and targeted drugs that inhibit DNA repair.

Hingorani M, White CL, Zaidi S, Pandha HS, Melcher AA, Bhide SA, Nutting CM, Syrigos KN, Vile RG, Vassaux G, Harrington KJ.

Mol Ther. 2010 Sep;18(9):1599-605. doi: 10.1038/mt.2010.120. Epub 2010 Jun 29.

40.

Disruption of HOX activity leads to cell death that can be enhanced by the interference of iron uptake in malignant B cells.

Daniels TR, Neacato II, Rodríguez JA, Pandha HS, Morgan R, Penichet ML.

Leukemia. 2010 Sep;24(9):1555-65. doi: 10.1038/leu.2010.142. Epub 2010 Jun 24.

41.

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers.

Harrington KJ, Karapanagiotou EM, Roulstone V, Twigger KR, White CL, Vidal L, Beirne D, Prestwich R, Newbold K, Ahmed M, Thway K, Nutting CM, Coffey M, Harris D, Vile RG, Pandha HS, Debono JS, Melcher AA.

Clin Cancer Res. 2010 Jun 1;16(11):3067-77. doi: 10.1158/1078-0432.CCR-10-0054. Epub 2010 May 18.

42.

Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.

Harrington KJ, Vile RG, Melcher A, Chester J, Pandha HS.

Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):91-8. doi: 10.1016/j.cytogfr.2010.02.006. Epub 2010 Mar 12. Review.

43.

Targeting HOX and PBX transcription factors in ovarian cancer.

Morgan R, Plowright L, Harrington KJ, Michael A, Pandha HS.

BMC Cancer. 2010 Mar 10;10:89. doi: 10.1186/1471-2407-10-89.

44.

Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma.

Pandha HS, Heinemann L, Simpson GR, Melcher A, Prestwich R, Errington F, Coffey M, Harrington KJ, Morgan R.

Clin Cancer Res. 2009 Oct 1;15(19):6158-66. doi: 10.1158/1078-0432.CCR-09-0796. Epub 2009 Sep 22.

45.

Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus.

Prestwich RJ, Errington F, Steele LP, Ilett EJ, Morgan RS, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

J Immunol. 2009 Oct 1;183(7):4312-21. doi: 10.4049/jimmunol.0901074. Epub 2009 Sep 4.

46.

The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Prestwich RJ, Errington F, Diaz RM, Pandha HS, Harrington KJ, Melcher AA, Vile RG.

Hum Gene Ther. 2009 Oct;20(10):1119-32. doi: 10.1089/hum.2009.135. Review.

47.

Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.

Prestwich RJ, Ilett EJ, Errington F, Diaz RM, Steele LP, Kottke T, Thompson J, Galivo F, Harrington KJ, Pandha HS, Selby PJ, Vile RG, Melcher AA.

Clin Cancer Res. 2009 Jul 1;15(13):4374-4381. doi: 10.1158/1078-0432.CCR-09-0334. Epub 2009 Jun 9.

48.

Dendritic cells and T cells deliver oncolytic reovirus for tumour killing despite pre-existing anti-viral immunity.

Ilett EJ, Prestwich RJ, Kottke T, Errington F, Thompson JM, Harrington KJ, Pandha HS, Coffey M, Selby PJ, Vile RG, Melcher AA.

Gene Ther. 2009 May;16(5):689-99. doi: 10.1038/gt.2009.29. Epub 2009 Mar 12.

49.

HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer).

Plowright L, Harrington KJ, Pandha HS, Morgan R.

Br J Cancer. 2009 Feb 10;100(3):470-5. doi: 10.1038/sj.bjc.6604857. Epub 2009 Jan 20.

50.

Inhibition of repair of radiation-induced DNA damage enhances gene expression from replication-defective adenoviral vectors.

Hingorani M, White CL, Merron A, Peerlinck I, Gore ME, Slade A, Scott SD, Nutting CM, Pandha HS, Melcher AA, Vile RG, Vassaux G, Harrington KJ.

Cancer Res. 2008 Dec 1;68(23):9771-8. doi: 10.1158/0008-5472.CAN-08-1911.

Supplemental Content

Loading ...
Support Center